The Supreme Court has decided to allow the abortion drug mifepristone to be distributed by mail, maintaining access as a legal battle continues. On Thursday (May 14), the court extended a stay on a previous ruling by the U.S. 5th Circuit Court of Appeals, which required women to obtain the drug through in-person visits rather than telehealth consultations. This decision ensures that mifepristone remains accessible by mail while the case, initiated by Louisiana against the Food and Drug Administration (FDA), unfolds in lower courts.
The case began when Louisiana sued the FDA over its decision to permit mail orders of mifepristone, arguing that it undermines the state’s abortion ban. The appeals court ruling would have reinstated pre-pandemic regulations requiring in-person dispensing of the drug. However, the Supreme Court’s order pauses this requirement, allowing continued mail access nationwide.
Justices Samuel Alito and Clarence Thomas dissented from the decision, expressing concerns about the implications for state regulation of abortion. Alito criticized the ruling as “unreasoned,” while Thomas referenced the Comstock Act, an 1873 law, to argue against mailing mifepristone.
The Supreme Court’s decision is not final, as the case returns to the 5th Circuit and could eventually reach the justices again. The FDA, which approved mifepristone in 2000, maintains that the drug is safe and effective, a stance supported by drugmakers Danco and GenBioPro. They argue that the appeals court’s decision would disrupt the FDA’s ongoing safety review and create confusion.
Despite the Supreme Court’s ruling, the legal battle over mifepristone continues to be a significant issue in the ongoing debate over abortion rights in the United States.
Recent Comments